Bacterial vaginosis (BV) is a common vaginal bacterial imbalance affecting about one in three women aged 14 to 49 in the United States. BV is characterized by unpleasant symptoms such as vaginal odor, discomfort, and potential health complications later in life. Unfortunately, over half of those seeking medical treatment for BV do not respond to the first-line antibiotic, metronidazole, leading to recurring infections.
To address this challenge, researchers at Drexel University have developed a simple, DNA-based PCR test that can better guide clinicians in prescribing the most effective treatment. Their findings, published in the journal Genome Medicine, provide hope for more targeted and effective management of BV.
The newly developed PCR test is built on a deeper genetic understanding of the bacterial organisms responsible for BV. Historically, Gardnerella vaginalis was believed to be the primary cause of BV. However, research led by Garth Ehrlich, PhD, professor of Microbiology and Immunology at Drexel, revealed that Gardnerella vaginalis is actually a complex group of related species.
Through genome sequencing of 129 strains of Gardnerella species, the researchers discovered significant diversity within this group. This analysis identified 11 distinct genospecies, organized into several major clades (groups), each of which behaves differently in response to treatment.
Notably, the team found that two of these clades contain genospecies that are completely resistant to metronidazole, the standard treatment for BV. These resistant strains can, however, be effectively treated with another antibiotic, clindamycin. The newly developed PCR test can distinguish these resistant strains, allowing for more precise treatment and reducing the likelihood of using ineffective antibiotics.
“For patients with metronidazole-resistant strains, this PCR test can help avoid unnecessary antibiotic treatment, reducing side effects and cost,” said Katherine Innamorati, PhD, lead author of the study and an instructor at Drexel University College of Medicine. “Faster treatment and better antibiotic stewardship are particularly important for patients who need multiple courses of antibiotics to fully eliminate the infection.”
BV is a condition that affects many women, often with little to no noticeable symptoms. About 50% of BV cases are asymptomatic, meaning they can go undiagnosed and untreated. The condition, if left untreated, can increase the risk of sexually transmitted infections (STIs), pregnancy complications, and other reproductive health problems.
Symptoms of BV may include vaginal itching, burning during urination, a foul odor, and unusual discharge, which may be gray, white, or green. While BV is not strictly considered a sexually transmitted infection, certain sexual activities, including unprotected sex, can increase the risk of developing it.
Current treatments for BV are not always effective, especially when the infection recurs. Metronidazole, the most commonly prescribed antibiotic, does not work for all patients, particularly those infected with metronidazole-resistant strains. The new PCR test helps identify patients who would benefit more from clindamycin, thus enhancing treatment outcomes and reducing unnecessary use of antibiotics.
Garth Ehrlich, PhD, emphasizes that BV is a dysbiosis, or an imbalance of the vaginal microbiome. Some patients may need both metronidazole and clindamycin to address the various microorganisms present, particularly anaerobic bacteria that thrive without oxygen. While more research is needed to determine the most effective combination therapy, the test will allow for more informed treatment decisions.
The Drexel team has filed for a patent for the PCR test, which could eventually be made available through commercial labs. However, widespread availability will depend on demand from patients and healthcare providers. The test is currently capable of identifying metronidazole-resistant strains, and future iterations aim to detect strains with lower resistance to the antibiotic.
The researchers are also exploring the genetic factors that contribute to antibiotic resistance in BV-causing bacteria. Understanding these genetic mechanisms could lead to the development of even more effective treatments in the future.
While this new test offers hope for more effective treatment and better management of BV, much work remains. Researchers are still investigating the specific genes responsible for resistance to metronidazole and exploring whether other treatments, such as a combination of antibiotics, may be needed for certain patients.
A recent randomized controlled trial published in the New England Journal of Medicine suggests that women with BV in a monogamous relationship may have a lower chance of recurrence if their male partner also receives antibiotic treatment, combined with the use of topical clindamycin cream. This emerging data highlights the importance of a comprehensive approach to BV treatment, involving both partners and the use of personalized diagnostics, such as the PCR test.
Ultimately, the development of the PCR test represents a significant step toward personalized, precision medicine for BV, allowing for more effective treatments and reducing the burden of this common yet challenging condition.
You Might Be Interested In:
-
Simultaneous Screening for Hypertension and Arrhythmia Could Prevent Strokes
-
Eating Ultra-Processed Food Daily Increases Depression Risk in Older Adults
